OSUR

$2.98

Post-MarketAs of Mar 17, 8:00 PM UTC

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Moby
Feb 26, 2026

OraSure Technologies, Inc. Q4 2025 Earnings Call Summary

Moby summary of OraSure Technologies, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 26, 2026

OraSure Technologies Q4 Earnings Call Highlights

OraSure Technologies (NASDAQ:OSUR) reported fourth-quarter 2025 revenue of $26.8 million, with management pointing to early signs of stabilization across key end markets after what it described as a transition year marked by a challenging funding environment. On the company’s earnings call, executiv

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 26, 2026

OraSure Technologies Inc (OSUR) Q4 2025 Earnings Call Highlights: Revenue Exceeds Expectations ...

Despite operating losses, OraSure Technologies Inc (OSUR) showcases strong revenue performance and strategic product expansions for 2026.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Feb 25, 2026

OraSure: Q4 Earnings Snapshot

OSUR) on Wednesday reported a loss of $19.3 million in its fourth quarter. On a per-share basis, the Bethlehem, Pennsylvania-based company said it had a loss of 27 cents. Losses, adjusted for non-recurring costs and stock option expense, were 19 cents per share.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 4, 2026

Phibro Animal Health (PAHC) Q2 Earnings and Revenues Surpass Estimates

Phibro (PAHC) delivered earnings and revenue surprises of +27.01% and +4.72%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.